Acetylsalicylic acid:
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
Weinheim
Wiley-VCH Verlag GmbH & Co. KGaA
[2016]
|
| Ausgabe: | Second edition |
| Schlagwörter: | |
| Links: | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028839858&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| Umfang: | XIII, 459 Seiten Illustrationen, Diagramme (farbig) |
| ISBN: | 9783527338054 9783527685059 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV043421942 | ||
| 003 | DE-604 | ||
| 005 | 20160831 | ||
| 007 | t| | ||
| 008 | 160302s2016 gw a||| |||| 00||| eng d | ||
| 020 | |a 9783527338054 |c Print |9 978-3-527-33805-4 | ||
| 020 | |a 9783527685059 |c oBook |9 978-3-527-68505-9 | ||
| 035 | |a (OCoLC)957468325 | ||
| 035 | |a (DE-599)BVBBV043421942 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-11 | ||
| 082 | 0 | |a 615.3137 |2 22/ger | |
| 084 | |a XI 4000 |0 (DE-625)153002:12905 |2 rvk | ||
| 100 | 1 | |a Schrör, Karsten |d 1942- |0 (DE-588)120284472 |4 aut | |
| 245 | 1 | 0 | |a Acetylsalicylic acid |c Karsten Schrör |
| 250 | |a Second edition | ||
| 264 | 1 | |a Weinheim |b Wiley-VCH Verlag GmbH & Co. KGaA |c [2016] | |
| 264 | 4 | |c © 2016 | |
| 300 | |a XIII, 459 Seiten |b Illustrationen, Diagramme (farbig) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Acetylsalicylsäure |0 (DE-588)4000351-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Acetylsalicylsäure |0 (DE-588)4000351-6 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-3-527-68504-2 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, MOBI |z 978-3-527-68503-5 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-3-527-68502-8 |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028839858&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-028839858 | |
Datensatz im Suchindex
| _version_ | 1819376848478404608 |
|---|---|
| adam_text | CONTENTS
PREFACE XIII
1 GENERAL ASPECTS 3
1.1 HISTORY 5
1.1.1 FROM WILLOW BARK TO SALICYLIC ACID 5
1.1.1.1 ANTI-INFLAMMATORY AND ANALGESIC EFFECTS OF WILLOW BARK AND
LEAVES 5
1.1.1.2 SALICYLATES AS THE ACTIVE INGREDIENTS OF WILLOW BARK AND OTHER
NATURAL SOURCES 6
1.1.1.3 CHEMICAL SYNTHESIS OF SALICYLIC ACID 6
SUMMARY 8
REFERENCES 8
1.1.2 SYNTHESIS OF ACETYLATED SALICYLIC ACID AND FIRST MEDICAL USE 9
1.1.2.1 THE INVENTION OF ACETYLATED SALICYLIC ACID 9
1.1.2.2 INTRODUCTION OF ACETYLSALICYLIC ACID INTO THE CLINICS 25
SUMMARY 16
REFERENCES 16
1.1.3 SEARCH FOR PHARMACOLOGICAL MODES OF ACTION 18
1.1.3.1 SALICYLATES AND ENERGY METABOLISM OF THE CELL 18
1.1.3.2 ASPIRIN AND PROSTAGLANDIN FORMATION 19
1.1.3.3 ASPIRIN AND COX-2 21
SUMMARY 23
REFERENCES 23
1.1.4 CLINICAL APPLICATIONS: A PIECE OF HISTORY 25
1.1.4.1 ANTI-INFLAMMATORY/ANALGESIC ACTIONS 25
1.1.4.2 ANTIPLATELET/ANTITHROMBOTIC ACTIONS AND THE BLEEDING TENDENCY 26
1.1.4.3 ASPIRIN AND THE HISTORY OF PREVENTION OF MYOCARDIAL INFARCTION
AND STROKE 27
SUMMARY 30
REFERENCES 30
1.1.5 CURRENT RESEARCH TOPICS 32
1.1.5.1 CLINICAL RESEARCH 32
1.1.5.2 BASIC RESEARCH 33
SUMMARY 39
REFERENCES 39
1.2 CHEMISTRY 41
1.2.1 STRUCTURES AND CHEMICAL PROPERTIES OF SALICYLATES 41
1.2.1.1 SALIERN: THE NATURAL SALICYLATE 41
1.2.1.2 SALICYLATES IN CLINICAL USE 41
1.2.1.3 ASPIRIN FORMULATIONS 43
SUMMARY 45
REFERENCES 46
1.2.2 DETERMINATION OF SALICYLATES 47
1.2.2.1 GAS-LIQUID CHROMATOGRAPHY 47
1.2.2.2 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 47
1.2.2.3 SPECTROPHOTOMETRY 47
SUMMARY 49
REFERENCES 49
2 PHARMACOLOGY 51
2.1 PHARMACOKINETICS 54
2.1.1 ABSORPTION AND DISTRIBUTION 54
2.1.1.1 ABSORPTION AND BIOAVAILABILITY 54
2.1.1.2 ASPIRIN FORMULATIONS 57
2.1.1.3 DISTRIBUTION AND PLASMA LEVELS 60
2.1.1.4 MODIFYING FACTORS 62
SUMMARY 63
REFERENCES 64
2.1.2 BIOTRANSFORMATION AND EXCRETION 66
2.1.2.1 ASPIRIN ESTERASES 66
2.1.2.2 BIO TRANSFORMATIONS OF SALICYLIC ACID 70
2.1.2.3 EXCRETION OF SALICYLATES 71
SUMMARY 72
REFERENCES 72
2.2 CELLULAR MODES OF ACTION 75
2.2.1 INHIBITION OF CYCLOOXYGENASES 76
2.2.1.1 COX-ISOFORMS, SUBSTRATES, AND REGULATION 76
2.2.1.2 INHIBITION/MODULATION OF CYCLOOXYGENASES BY ASPIRIN 78
2.2.1.3 THE DIFFERENT PHARMACOLOGY OF ASPIRIN AND NSAIDS 82
2.2.1.4 MODULATION OF COX-2 GENE EXPRESSION 84
2.2.1.5
FURTHER ACTIONS OF SALICYLATES ON LIPID MEDIATORS
85
SUMMARY
85
REFERENCES
86
2.2.2
COX-INDEPENDENT ACTIONS OF ASPIRIN ON CELL FUNCTION
89
2.2.2.1
SALICYLATES IN THE PLANT KINGDOM
89
2 2 2 2
TRANSACETYLATION ACTIONS BY ASPIRIN
89
2 2 2 3
ASPIRIN AND NITRIC OXIDE FORMATION 91
2 2 2 A
SALICYLATES AND KINASES
92
2 2 2 3
SALICYLATES AND TRANSCRIPTION FACTORS
96
SUMMARY
98
REFERENCES
99
2.2.3
ENERGY METABOLISM
101
2.2.3.1
DIFFERENT PHARMACODYNAMICS OF ASPIRIN AND SALICYLATES
101
2.23.2 FATTY ACID SS-OXIDATION
102
2.2.33
UNCOUPLING OF OXIDATIVE PHOSPHORYLATION
106
2.23.4 METABOLIC ACTIONS OF SALICYLATES AND REYE*S SYNDROME
108
SUMMARY
109
REFERENCES
110
2.3
ACTIONS ON ORGANS AND TISSUES
113
2.3.1 HEMOSTASIS AND THROMBOSIS
113
23.1.1 GENERAL ASPECTS
113
23.1.2 PLATELETS
115
2.3.13 ENDOTHELIAL CELLS
123
23.1.4 PLASMATIC COAGULATION
128
23.1.5 FIBRINOLYSIS
128
SUMMARY 129
REFERENCES
130
2.3.2
INFLAMMATION, PAIN, AND FEVER
136
23.2.1
GENERAL ASPECTS
136
23.2.2
INFLAMMATION
137
2.3.23 PAIN
142
23.2.4
FEVER
147
SUMMARY
149
REFERENCES
150
2.3.3
ASPIRIN AND MALIGNANCIES
153
2.33.1
GENERAL ASPECTS
153
2.33.2
PATHOPHYSIOLOGY
154
2.3.33
MODES OF ASPIRIN ACTION
156
2.33.4 COX-RELATED ACTIONS OF ASPIRIN
157
23.3.5 NON-COX-RELATED ANTITUMOR ACTIONS OF ASPIRIN
160
SUMMARY
162
REFERENCES
162
3 TOXICITY AND DRUG SAFETY 167
3.1 SYSTEMIC SIDE EFFECTS 170
3.1.1 ACUTE AND CHRONIC TOXICITY 170
3.1.1.1 GENERAL ASPECTS 170
3.1.1.2 PATHOPHYSIOLOGY AND CLINICAL SYMPTOMS OF ACUTE OVERDOSING 172
3.1.1.3 TREATMENT 175
3.1.1.4 HABITUATION 177
SUMMARY 177
REFERENCES 178
3.1.2 BLEEDING TIME AND BLEEDING RISK 180
3.1.2.1 ASPIRIN AND BLEEDING TIME 180
3.1.2.2 MODE OF ASPIRIN ACTION 181
3.1.2.3 ASPIRIN-RELATED BLEEDING RISK IN LONG-TERM PREVENTION AND ACUTE
SURGICAL
INTERVENTIONS 184
3.1.2.4 PREVENTION AND TREATMENT OF BLEEDINGS 186
SUMMARY 187
REFERENCES 188
3.1.3 SAFETY PHARMACOLOGY IN PARTICULAR LIFE SITUATIONS 191
3.1.3.1 PREGNANCY AND FETAL DEVELOPMENT 191
3.1.3.2 THE ELDERLY PATIENT 193
SUMMARY 195
REFERENCES 195
3.2 ORGAN TOXICITY 198
3.2.1 GASTROINTESTINAL (GL) TRACT 198
3.2.1.1 GENERAL ASPECTS 198
3.2.1.2 PATHOPHYSIOLOGY OF ASPIRIN-INDUCED GI INJURY 199
3.2.1.3 MODE OF ASPIRIN ACTION 201
3.2.1.4 CLINICAL STUDIES 205
3.2.1.5 ASPIRIN AND OTHER DRUGS 209
SUMMARY 211
REFERENCES 211
3.2.2 LIVER 216
3.2.2.1 GENERAL ASPECTS 216
3.2.2.2 PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION 216
3.2.2.3 CLINICAL STUDIES 217
SUMMARY 217
REFERENCES 218
3.2.3 KIDNEY 219
3.2.3.1 GENERAL ASPECTS 219
3.2.3.2 ANALGESIC NEPHROPATHY AND ITS PATHOPHYSIOLOGY 219
3.2.33 MODE OF ASPIRIN ACTION 220
3.23.4 CLINICAL STUDIES - INDIVIDUALS WITHOUT KIDNEY DISEASES 221
3.23.5 CLINICAL STUDIES - INDIVIDUALS WITH PREEXISTING KIDNEY DISEASES
223
SUMMARY 225
REFERENCES 226
3.2.4 AUDIOVESTIBULAR SYSTEM 228
3.2.4.1 GENERAL ASPECTS 228
3.2.4.2 PATHOPHYSIOLOGY OF ASPIRIN-INDUCED HEARING LOSS AND TINNITUS 228
3.2.43 MODE OF ASPIRIN ACTION 228
3.2.4.4 CLINICAL STUDIES 230
SUMMARY 231
REFERENCES 231
3.3 HYPERSENSITIVITY TO ASPIRIN AND REYE S SYNDROME 233
3.3.1 ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD, ASPIRIN-INDUCED
ASTHMA ) 233
33.1.1 HISTORY, EPIDEMIOLOGY, AND PATHOPHYSIOLOGY 233
33.1.2 MODE OF ASPIRIN ACTION 237
3.3.13 CLINICAL STUDIES 239
33.1.4 ASPIRIN AND OTHER DRUGS 240
SUMMARY 240
REFERENCES 241
3.3.2 URTICARIA/ANGIOEDEMA AND STEVENS-JOHNSON AND LYELL S SYNDROME 244
33.2.1 URTICARIA/ANGIOEDEMA 244
33.2.2 STEVENS-JOHNSON SYNDROME AND LYELL S SYNDROME 245
SUMMARY 245
REFERENCES 245
3.3.3 REYE S SYNDROME 247
3.33.1 CLINICS, LABORATORY AND MORPHOLOGICAL FINDINGS 248
3.33.2 ETIOLOGY AND PATHOGENESIS 249
3.3.33 CLINICAL STUDIES 252
3.33.4 ACTUAL SITUATION 256
SUMMARY 258
REFERENCES 259
4 CLINICAL APPLICATIONS OF ASPIRIN 263
4.1 THROMBOEMBOLIC DISEASES 268
4.1.1 CORONARY VASCULAR DISEASE 269
4.1.1.1 GENERAL ASPECTS 269
4.1.1.2 THROMBOTIC RISK AND MODE OF ASPIRIN ACTION 271
4.1.13 CLINICAL TRIALS: PRIMARY PREVENTION IN APPARENTLY HEALTHY
INDIVIDUALS 275
4.1.1.4 CLINICAL TRIALS: PRIMARY PREVENTION IN INDIVIDUALS WITH VASCULAR
RISK FACTORS
279
4.1.1.5 CLINICAL TRIALS: CARDIOVASCULAR PREVENTION IN PATIENTS WITH
STABLE ANGINA 284
4.1.1.6 CLINICAL TRIALS: ACUTE CORONARY SYNDROMES (ACS) 285
4.1.1.7 CLINICAL TRIALS: LONG-TERM SECONDARY PREVENTION 288
4.1.1.8 CLINICAL TRIALS: CORONARY ARTERY BYPASS GRAFT SURGERY (CABG) AND
OTHER SURGICAL
INTERVENTIONS 291
4.1.1.9 ASPIRIN AND OTHER DRUGS 292
4.1.1.10 ACTUAL SITUATION 297
SUMMARY 298
REFERENCES 299
4.1.2 CEREBROVASCULAR DISEASES 307
4.1.2.1 GENERAL ASPECTS 307
4.1.2.2 THROMBOTIC RISK AND MODE OF ASPIRIN ACTION 308
4.1.2.3 CLINICAL TRIALS: PRIMARY PREVENTION 312
4.1.2.4 CLINICAL TRIALS: SECONDARY PREVENTION 314
4.1.2.5 ASPIRIN AND OTHER DRUGS 318
4.1.2.6 ACTUAL SITUATION 323
SUMMARY 324
REFERENCES 325
4.1.3 PERIPHERAL ARTERIAL DISEASE 330
4.1.3.1 GENERAL ASPECTS 330
4.1.3.2 THROMBOTIC RISK AND MODE OF ASPIRIN ACTION 330
4.1.3.3 CLINICAL TRIALS: PRIMARY PREVENTION 332
4.1.3.4 CLINICAL TRIALS: SECONDARY PREVENTION 334
4.1.3.5 CLINICAL TRIALS: PERIPHERAL TRANSLUMINAL ANGIOPLASTY (PTA)
AND SURGICAL INTERVENTIONS 336
4.1.3.6 ASPIRIN AND OTHER DRUGS 337
4.1.3.7 ACTUAL SITUATION 339
SUMMARY 339
REFERENCES 339
4.1.4 VENOUS THROMBOSIS 343
4.1.4.1 GENERAL ASPECTS 343
4.1.4.2 THROMBOTIC RISK AND MODE OF ASPIRIN ACTION 343
4.1.4.3 CLINICAL TRIALS: PRIMARY PREVENTION 344
4.1.4.4 CLINICAL TRIALS: SECONDARY PREVENTION 348
4.1.4.5 ASPIRIN AND OTHER DRUGS 350
4.1.4.6 ACTUAL STATUS 350
SUMMARY 351
REFERENCES 351
4.1.5 PREECLAMPSIA 354
4.1.5.1 GENERAL ASPECTS 354
4.1.5.2 THROMBOTIC RISK AND MODE OF ASPIRIN ACTION 354
4.1.5.3 CLINICAL TRIALS: EARLY STUDIES 358
4.1.5.4 CLINICAL TRIALS: REASONS FOR DATA VARIABILITY 359
4.1.5.5 ACTUAL SITUATION 363
SUMMARY 364
REFERENCES 365
4.1.6 ASPIRIN RESISTANCE (HIGH ON-ASPIRIN TREATMENT PLATELET
REACTIVITY) 369
4.1.6.1 GENERAL ASPECTS 369
4.1.6.2 DEFINITION AND TYPES OF PHARMACOLOGICAL ASPIRIN *RESISTANCE*
(HTPR) 370
4.1.6.3 DETECTION OF ASPIRIN *RESISTANCE* AND POSSIBLE PITFALLS IN ITS
DETERMINATION 371
4.1.6.4 PHENOTYPES OF ASPIRIN *RESISTANCE* (HTPR) 373
4.1.6.5 CLINICAL TRIALS 379
4.1.6.6 ACTUAL SITUATION 383
SUMMARY 383
REFERENCES 384
4.2 PAIN, FEVER, AND INFLAMMATORY DISEASES 389
4.2.1 ANALGESIA AND ANTIPYRESIS 390
4.2.1.1 GENERAL ASPECTS 390
4.2.1.2 PAIN, FEVER, AND MODE OF ANALGESIC/ANTIPYRETIC ASPIRIN ACTION
390
4.2.1.3 CLINICAL TRIALS 394
4.2.1.4 ASPIRIN AND OTHER DRUGS 397
4.2.1.5 ACTUAL SITUATION 397
SUMMARY 397
REFERENCES 398
4.2.2 INFLAMMATORY DISEASES 401
4.2.2.1 GENERAL ASPECTS 401
42.2.2 RHEUMATOID ARTHRITIS: PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION
402
4.2.23 OSTEOARTHRITIS: PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION 403
4.2.2.4 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS): PATHOPHYSIOLOGY
AND MODE OF ASPIRIN ACTION 403
4.2.2.5 HIV: PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION 404
4.22.6 CLINICAL TRIALS 405
4.22.7 ASPIRIN AND OTHER DRUGS 407
4.2.2.5 ACTUAL SITUATION 410
SUMMARY 410
REFERENCES 411
4.2.3 KAWASAKI S DISEASE 414
4.2.3.1 GENERAL ASPECTS 414
4.23.2 PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION 414
4.2.3.3 CLINICAL TRIALS 415
4.2.3.4 ASPIRIN AND OTHER DRUGS 416
4.2.3.5 ACTUAL SITUATION 416
SUMMARY 416
REFERENCES 417
4.3
FURTHER POTENTIAL CLINICAL INDICATIONS
418
4.3.1 COLORECTAL CANCER 418
4.3.1.1 GENERAL ASPECTS 418
4.3.1.2 PATHOPHYSIOLOGY OF INTESTINAL NEOPLASIAS 419
4.3.1.3 MODE OF ASPIRIN ACTION 419
4.3.1.4 CLINICAL TRIALS: PRIMARY PREVENTION 423
4.3.1.5 CLINICAL TRIALS: SECONDARY PREVENTION 428
4.3.1.6 ASPIRIN, OTHER DRUGS, AND ENVIRONMENTAL FACTORS 431
4.3.1.7 ACTUAL SITUATION 432
SUMMARY 434
REFERENCES 434
4.3.2 ALZHEIMER S DISEASE 438
4.3.2.1 GENERAL ASPECTS 438
4.3.2.2 PATHOPHYSIOLOGY AND MODE OF ASPIRIN ACTION 438
4.3.2.3 CLINICAL TRIALS 440
4.3.2.4 ASPIRIN AND OTHER DRUGS 444
4.3.2.5 ACTUAL SITUATION 444
SUMMARY 444
REFERENCES 445
APPENDIX 1: ABBREVIATIONS 447
APPENDIX 2: SELECTED CLINICAL TRIALS AND THEIR ACRONYMS - ONLY PUBLISHED
TRIALS 449
INDEX 453
|
| any_adam_object | 1 |
| author | Schrör, Karsten 1942- |
| author_GND | (DE-588)120284472 |
| author_facet | Schrör, Karsten 1942- |
| author_role | aut |
| author_sort | Schrör, Karsten 1942- |
| author_variant | k s ks |
| building | Verbundindex |
| bvnumber | BV043421942 |
| classification_rvk | XI 4000 |
| ctrlnum | (OCoLC)957468325 (DE-599)BVBBV043421942 |
| dewey-full | 615.3137 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.3137 |
| dewey-search | 615.3137 |
| dewey-sort | 3615.3137 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | Second edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01731nam a2200433 c 4500</leader><controlfield tag="001">BV043421942</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160831 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">160302s2016 gw a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527338054</subfield><subfield code="c">Print</subfield><subfield code="9">978-3-527-33805-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527685059</subfield><subfield code="c">oBook</subfield><subfield code="9">978-3-527-68505-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)957468325</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043421942</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-11</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.3137</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4000</subfield><subfield code="0">(DE-625)153002:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schrör, Karsten</subfield><subfield code="d">1942-</subfield><subfield code="0">(DE-588)120284472</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Acetylsalicylic acid</subfield><subfield code="c">Karsten Schrör</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Second edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH Verlag GmbH & Co. KGaA</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 459 Seiten</subfield><subfield code="b">Illustrationen, Diagramme (farbig)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Acetylsalicylsäure</subfield><subfield code="0">(DE-588)4000351-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Acetylsalicylsäure</subfield><subfield code="0">(DE-588)4000351-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-3-527-68504-2</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, MOBI</subfield><subfield code="z">978-3-527-68503-5</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-3-527-68502-8</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028839858&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028839858</subfield></datafield></record></collection> |
| id | DE-604.BV043421942 |
| illustrated | Illustrated |
| indexdate | 2024-12-20T17:36:00Z |
| institution | BVB |
| isbn | 9783527338054 9783527685059 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028839858 |
| oclc_num | 957468325 |
| open_access_boolean | |
| owner | DE-11 |
| owner_facet | DE-11 |
| physical | XIII, 459 Seiten Illustrationen, Diagramme (farbig) |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Wiley-VCH Verlag GmbH & Co. KGaA |
| record_format | marc |
| spellingShingle | Schrör, Karsten 1942- Acetylsalicylic acid Pharmakologie (DE-588)4045687-0 gnd Acetylsalicylsäure (DE-588)4000351-6 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4000351-6 |
| title | Acetylsalicylic acid |
| title_auth | Acetylsalicylic acid |
| title_exact_search | Acetylsalicylic acid |
| title_full | Acetylsalicylic acid Karsten Schrör |
| title_fullStr | Acetylsalicylic acid Karsten Schrör |
| title_full_unstemmed | Acetylsalicylic acid Karsten Schrör |
| title_short | Acetylsalicylic acid |
| title_sort | acetylsalicylic acid |
| topic | Pharmakologie (DE-588)4045687-0 gnd Acetylsalicylsäure (DE-588)4000351-6 gnd |
| topic_facet | Pharmakologie Acetylsalicylsäure |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028839858&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schrorkarsten acetylsalicylicacid |